- Home
- FURY vs QNCX Comparison
FURY vs QNCX Comparison
Compare FURY & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- QNCX
- Stock Information
- Founded
- FURY 2008
- QNCX 2012
- Country
- FURY Canada
- QNCX United States
- Employees
- FURY N/A
- QNCX N/A
- Industry
- FURY Precious Metals
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FURY Basic Materials
- QNCX Health Care
- Exchange
- FURY Nasdaq
- QNCX Nasdaq
- Market Cap
- FURY 84.1M
- QNCX 88.6M
- IPO Year
- FURY N/A
- QNCX 2019
- Fundamental
- Price
- FURY $0.55
- QNCX $1.57
- Analyst Decision
- FURY Strong Buy
- QNCX Strong Buy
- Analyst Count
- FURY 2
- QNCX 4
- Target Price
- FURY $1.40
- QNCX $7.75
- AVG Volume (30 Days)
- FURY 985.2K
- QNCX 199.5K
- Earning Date
- FURY 11-11-2025
- QNCX 11-12-2025
- Dividend Yield
- FURY N/A
- QNCX N/A
- EPS Growth
- FURY N/A
- QNCX N/A
- EPS
- FURY N/A
- QNCX N/A
- Revenue
- FURY N/A
- QNCX N/A
- Revenue This Year
- FURY N/A
- QNCX N/A
- Revenue Next Year
- FURY N/A
- QNCX N/A
- P/E Ratio
- FURY N/A
- QNCX N/A
- Revenue Growth
- FURY N/A
- QNCX N/A
- 52 Week Low
- FURY $0.35
- QNCX $0.72
- 52 Week High
- FURY $0.89
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- FURY 38.83
- QNCX 38.91
- Support Level
- FURY $0.52
- QNCX $1.52
- Resistance Level
- FURY $0.60
- QNCX $1.66
- Average True Range (ATR)
- FURY 0.04
- QNCX 0.09
- MACD
- FURY -0.01
- QNCX -0.02
- Stochastic Oscillator
- FURY 17.24
- QNCX 32.18
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.